NYSE:PKI
USD
137.53
0.03 (0.02%)
PERKINELMER, INC.
Industry: Diagnostics & Research
End of Day: 31 January 2023 GMT-5
USD 137.53
0.030 (0.02%)
End of Day: 31 January 2023 GMT-5
Industry: Diagnostics & Research

Quote

Market Cap
17.372b
1M Daily Avg. Vol
869.450k
3Y P/B Range
2.1 - 4.5
52W Range
113.46 - 190.56
3Y P/S Range
2.7 - 5
3Y DivYield Range
0.1 - 0.4

Company Info

more

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segmen...

Key Ratios

more

3Y Rev Growth
19.50%
3Y Operating Profit Growth
39.90%
Operating Margin
20.60%
FCF Margin
16.00%
ROE
8.80%
ROA
4.50%

Income

more

Total Revenues (USD, MM)
4.84k
Net Income (USD, MM)
631.00
Net Margin
14.00%

Balance Sheet

more

Total Assets (USD, MM)
13.82k
Total Liabilities (USD, MM)
6.76k
Book Value Per Share
56.00

Cash Flow

more

Operations (USD, MM)
876.00
Investing (USD, MM)
-167.00
Financing (USD, MM)
-724.00

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Investment summary

Firms can create value for their investors in many different ways, ranging from capital appreciation of equity, return of capital (dividends, buybacks), and through acquisitions. Each scenario is typically underpinned by the fundamental drivers of...

more

PerkinElmer Announces Quarterly Dividend of $0.07 per Share

Trending News

PerkinElmer, a global leader in life sciences, diagnostics, and analytical technologies, announced its quarterly dividend of $0.07 per share. This payment is in line with the company’s previous quarterly dividend payments and is payable on May 12th to shareholders of record as of...

more

Investing $10K in PerkinElmer Over 5 Years Yields Impressive Results!

Trending News

Investing $10K in PerkinElmer over five years has proven to be a wise decision, yielding impressive results. PerkinElmer is a global leader in the development and production of technology for the life sciences, industrial, and diagnostics markets. PerkinElmer is committed to...

more

PerkinElmer declares $0.07 dividend

  • PerkinElmer (NYSE:PKI) declares $0.07/share quarterly dividend, in line with previous.
  • Payable May 12; for shareholders of record April 21; ex-div April 20.
  • See PKI Dividend Scorecard, Yield Chart, & Dividend Growth.
...

https://seekingalpha.com/news/39286...

$NYSE:PKI

...

more

Danaher earnings weigh on other life sciences tools, services companies

  • Danaher (NYSE:DHR), which reported slowing topline growth in its Q4 2022 financial results earlier Tuesday, is impacting other life sciences tools and services providers.
  • The biggest decliner among peers is Repligen...

more

PerkinElmer, Inc. (PKI) 41st Annual J.P. Morgan Healthcare Conference (Transcript)

PerkinElmer, Inc. (PKI)

41st Annual J.P. Morgan Healthcare Conference Call

January 10, 2023 11:15 AM ET

Company Participants

Prahlad Singh - President and Chief Executive Officer

Conference Call...

more

PerkinElmer Exceeds Q4 2022 Guidance Expectations

Trending News

PerkinElmer Inc. is a global leader in the life sciences, healthcare, and applied markets, providing customers with solutions to detect, protect, and cure. The news has been received positively by the market and has led to a surge in the stock price of PerkinElmer. Analysts are...

more

PerkinElmer says Q4 results will meet or exceed prior guidance

  • PerkinElmer (NYSE:PKI) said that it expects its Q4 2022 results to meet or exceed guidance given in November.

  • Back then, the life sciences company projected pro forma total revenue is $1.06B-$1.07B vs. consensus of...

more

PerkinElmer Inc, 0.07, Cash Dividend, 2023-01-19

PerkinElmer Inc, 0.07, Cash Dividend, 2023-01-19

$NYSE:PKI

Could PerkinElmer Be The Next Danaher?

Can a restructuring lead to outperformance?

PerkinElmer, Inc. (PKI) is an American Medical Devices company focused on life sciences and diagnostics. Over the last ten years, the company outperformed the S&P 500 by a wide margin but did not manage to beat the...

more

All statements, views or opinions expressed here are the personal views of our users. They do not represent nor should they be construed as representing our statements, views or opinions. For the avoidance of doubt, any such statements, views or opinions are not and shall not be construed as financial advice.

Make Smart Investment Choices